Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Visual impairment due to CNV secondary to PM.~* Best corrected visual acuity in the study eye \> 24 and \< 78 ETDRS letters.~* High myopia (\> -6D),~* anterio-posterior elongation \> 26 mm; posterior changes compatible with the pathologic myopia.~* Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.~Exclusion Criteria:~* Some preexisting eye disorders or systemic diseases;-Blood pressure \> 150/90 mmHg~* Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF or verteporfin PDT in the study eye~* Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): 0.5 mg ranibizumab driven by visual acuity stability criteria
- Group II (Type: EXPERIMENTAL): 0.5 mg ranibizumab driven by disease activity criteria
- Group III (Type: ACTIVE_COMPARATOR): verteporfin PDT

Based on this trial design, predict the completion outcome and termination type (if applicable).